Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05848219 · ClinicalTrials.gov registry record
Healthcare Resource Utilization and Costs in Metastatic Melanoma Patients Initiated Dabrafenib + Trametinib and Encorafenib + Binimetinib
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Terminated
- Registry status
- 543
- Enrollment target
NCT05848219: Clinical Trial study, sponsored by Novartis Pharmaceuticals.
NCT05848219 is a clinical trial that was terminated before completion, run by Novartis Pharmaceuticals. The registered enrollment target is 543 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05848219 was terminated before completion, sponsored by Novartis Pharmaceuticals.
- TERMINATED
- Registry status
- 543 participants
- Enrollment target
Study Summary
This was a retrospective cohort study using the MarketScan health care administrative claim databases: Truven Health Analytics' MarketScan Commercial Claims and Encounters; MarketScan Medicare Supplement and Coordination of Benefit. We conducted this analysis using the most recent available data from the MarketScan database at the time of analysis, which was 01 June 2018 to 31 December 2020. We initiated this analysis from 01 June 2018 as encorafenib + binimetinib (enco/bini) was approved for patients with unresectable or metastatic melanoma with BRAF mutation at this time.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 543 participants |
| Start Date | 2021-10-16 |
| Est. Completion | 2022-04-27 |
Why NCT05848219 stopped before completion
NCT05848219 is an observational study that tracks outcomes without assigning an intervention. The registered 543 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT05848219 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05848219 about?
NCT05848219 is a clinical study titled "Healthcare Resource Utilization and Costs in Metastatic Melanoma Patients Initiated Dabrafenib + Trametinib and Encorafenib + Binimetinib". This was a retrospective cohort study using the MarketScan health care administrative claim databases: Truven Health Analytics' MarketScan Commercial Claims and Encounters; MarketScan Medicare Supplement and Coordination of Benefit. We conducted this analysis using the most recent available data fro...
What is the current status of trial NCT05848219?
This trial is currently terminated. The enrollment target is 543 participants. The study started on 2021-10-16. Estimated completion is 2022-04-27.
Who is sponsoring clinical trial NCT05848219?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07294053 · 543 participants · NA
Sugary Drink Labeling Study
- NCT03127761 · 544 participants
Assessment of Allogeneic Hematopoietic Cell Transplantation in Medicare Beneficiaries With Multiple Myeloma
- NCT04378790 · 544 participants · Phase 3
A Randomized Trial to Evaluate Sequential vs Simultaneous Patching
- NCT06118502 · 544 participants · NA
A Clinical Trial of Adaptive Treatment for Early Smoking Cessation Relapse
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI